Pharmacokinetics of a new human plasma-derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients.

MLA

Castaman, Giancarlo, et al. “Pharmacokinetics of a New Human Plasma-Derived Double Virus Inactivated and Nanofiltered Factor IX Concentrate in Previously Treated Severe or Moderately Severe Haemophilia B Patients.” Haemophilia : The Official Journal of the World Federation of Hemophilia, vol. 25, no. 6, Nov. 2019, pp. e364–67. EBSCOhost, https://doi.org/10.1111/hae.13828.

APA

Castaman, G., Borchiellini, A., Santagostino, E., Tagariello, G., Serban, M., Uscatescu, M., Truica, C., Farrugia, A., & Morfini, M. (2019). Pharmacokinetics of a new human plasma-derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients. Haemophilia : The Official Journal of the World Federation of Hemophilia, 25(6), e364–e367. https://doi.org/10.1111/hae.13828

Chicago

Castaman, Giancarlo, Alessandra Borchiellini, Elena Santagostino, Giuseppe Tagariello, Margit Serban, Marusia Uscatescu, Cristina Truica, Albert Farrugia, and Massimo Morfini. 2019. “Pharmacokinetics of a New Human Plasma-Derived Double Virus Inactivated and Nanofiltered Factor IX Concentrate in Previously Treated Severe or Moderately Severe Haemophilia B Patients.” Haemophilia : The Official Journal of the World Federation of Hemophilia 25 (6): e364–67. doi:10.1111/hae.13828.